Dermatomycoses Drug
Dermatomycoses Drug market is segmented by region (country), players, by Type and by Application. ... Read More
Global and United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Report & Forecast 2024-2031
1 Study Coverage
1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size for the Year 2017-2028
1.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size for the Year 2017-2028
1.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Squamous Non-Small Cell Lung Cancer Therapeutics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics
1.4.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends
1.4.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
1.4.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
1.4.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Squamous Non-Small Cell Lung Cancer Therapeutics by Type
2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment by Type
2.1.1 BMS-906024
2.1.2 Buparlisib Hydrochloride
2.1.3 FP-1039
2.1.4 Ipilimumab
2.1.5 JNJ-42756493
2.1.6 Lenvatinib
2.1.7 Others
2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017, 2022 & 2028)
2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017-2028)
2.4 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017, 2022 & 2028)
2.5 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017-2028)
3 Squamous Non-Small Cell Lung Cancer Therapeutics by Application
3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Segment by Application
3.1.1 Research Center
3.1.2 Hospital
3.1.3 Clinic
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017, 2022 & 2028)
3.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017-2028)
3.4 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017, 2022 & 2028)
3.5 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017-2028)
4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Competitor Landscape by Company
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Company
4.1.1 Top Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Ranked by Revenue (2021)
4.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Player (2017-2022)
4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Concentration Ratio (CR)
4.2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Squamous Non-Small Cell Lung Cancer Therapeutics in 2021
4.2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Headquarters, Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Headquarters and Area Served
4.3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Company
4.5.1 Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players (2020, 2021 & 2022)
5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region
5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2017-2028)
5.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region: 2017-2022
5.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.1.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.3.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.4.2 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Ascenta Therapeutics, Inc.
7.1.1 Ascenta Therapeutics, Inc. Company Details
7.1.2 Ascenta Therapeutics, Inc. Business Overview
7.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.1.4 Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.1.5 Ascenta Therapeutics, Inc. Recent Development
7.2 AstraZeneca Plc
7.2.1 AstraZeneca Plc Company Details
7.2.2 AstraZeneca Plc Business Overview
7.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.2.4 AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.2.5 AstraZeneca Plc Recent Development
7.3 AVEO Pharmaceuticals, Inc.
7.3.1 AVEO Pharmaceuticals, Inc. Company Details
7.3.2 AVEO Pharmaceuticals, Inc. Business Overview
7.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.3.4 AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.3.5 AVEO Pharmaceuticals, Inc. Recent Development
7.4 Bayer AG
7.4.1 Bayer AG Company Details
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.4.4 Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.4.5 Bayer AG Recent Development
7.5 BIND Therapeutics, Inc.
7.5.1 BIND Therapeutics, Inc. Company Details
7.5.2 BIND Therapeutics, Inc. Business Overview
7.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.5.4 BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.5.5 BIND Therapeutics, Inc. Recent Development
7.6 Boehringer Ingelheim GmbH
7.6.1 Boehringer Ingelheim GmbH Company Details
7.6.2 Boehringer Ingelheim GmbH Business Overview
7.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.6.4 Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.6.5 Boehringer Ingelheim GmbH Recent Development
7.7 Bristol-Myers Squibb Company
7.7.1 Bristol-Myers Squibb Company Company Details
7.7.2 Bristol-Myers Squibb Company Business Overview
7.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.7.4 Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.7.5 Bristol-Myers Squibb Company Recent Development
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Company Details
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.8.4 Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.8.5 Eli Lilly and Company Recent Development
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 F. Hoffmann-La Roche Ltd. Company Details
7.9.2 F. Hoffmann-La Roche Ltd. Business Overview
7.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.9.4 F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.9.5 F. Hoffmann-La Roche Ltd. Recent Development
7.10 Five Prime Therapeutics, Inc.
7.10.1 Five Prime Therapeutics, Inc. Company Details
7.10.2 Five Prime Therapeutics, Inc. Business Overview
7.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.10.4 Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.10.5 Five Prime Therapeutics, Inc. Recent Development
7.11 Genentech, Inc.
7.11.1 Genentech, Inc. Company Details
7.11.2 Genentech, Inc. Business Overview
7.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.11.4 Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.11.5 Genentech, Inc. Recent Development
7.12 Incyte Corporation
7.12.1 Incyte Corporation Company Details
7.12.2 Incyte Corporation Business Overview
7.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.12.4 Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.12.5 Incyte Corporation Recent Development
7.13 Johnson & Johnson
7.13.1 Johnson & Johnson Company Details
7.13.2 Johnson & Johnson Business Overview
7.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.13.4 Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.13.5 Johnson & Johnson Recent Development
7.14 MacroGenics, Inc.
7.14.1 MacroGenics, Inc. Company Details
7.14.2 MacroGenics, Inc. Business Overview
7.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.14.4 MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.14.5 MacroGenics, Inc. Recent Development
7.15 Novartis AG
7.15.1 Novartis AG Company Details
7.15.2 Novartis AG Business Overview
7.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.15.4 Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.15.5 Novartis AG Recent Development
7.16 Oncogenex Pharmaceuticals, Inc.
7.16.1 Oncogenex Pharmaceuticals, Inc. Company Details
7.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview
7.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.16.4 Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.16.5 Oncogenex Pharmaceuticals, Inc. Recent Development
7.17 PsiOxus Therapeutics Limited
7.17.1 PsiOxus Therapeutics Limited Company Details
7.17.2 PsiOxus Therapeutics Limited Business Overview
7.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Introduction
7.17.4 PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
7.17.5 PsiOxus Therapeutics Limited Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Tables
Table 1. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
Table 2. Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends
Table 3. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
Table 4. Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
Table 5. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
Table 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Squamous Non-Small Cell Lung Cancer Therapeutics Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Player, (US$ Million), 2017-2022
Table 12. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Player, 2017-2022
Table 13. Global Squamous Non-Small Cell Lung Cancer Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2021)
Table 15. Top Players of Squamous Non-Small Cell Lung Cancer Therapeutics in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million) Type
Table 17. Date of International Companies Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Squamous Non-Small Cell Lung Cancer Therapeutics Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 21. United States Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Players, 2020, 2021 & 2022
Table 22. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 23. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 24. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region (2023-2028) & (US$ Million)
Table 25. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 26. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Region (2017-2028) & (US$ Million)
Table 27. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 28. Latin Americaa Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 29. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
Table 30. Ascenta Therapeutics, Inc. Company Details
Table 31. Ascenta Therapeutics, Inc. Business Overview
Table 32. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 33. Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 34. Ascenta Therapeutics, Inc. Recent Development
Table 35. AstraZeneca Plc Company Details
Table 36. AstraZeneca Plc Business Overview
Table 37. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 38. AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 39. AstraZeneca Plc Recent Development
Table 40. AVEO Pharmaceuticals, Inc. Company Details
Table 41. AVEO Pharmaceuticals, Inc. Business Overview
Table 42. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 43. AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 44. AVEO Pharmaceuticals, Inc. Recent Development
Table 45. Bayer AG Company Details
Table 46. Bayer AG Business Overview
Table 47. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 48. Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Bayer AG Recent Development
Table 50. BIND Therapeutics, Inc. Company Details
Table 51. BIND Therapeutics, Inc. Business Overview
Table 52. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 53. BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 54. BIND Therapeutics, Inc. Recent Development
Table 55. Boehringer Ingelheim GmbH Company Details
Table 56. Boehringer Ingelheim GmbH Business Overview
Table 57. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 58. Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Boehringer Ingelheim GmbH Recent Development
Table 60. Bristol-Myers Squibb Company Company Details
Table 61. Bristol-Myers Squibb Company Business Overview
Table 62. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 63. Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Bristol-Myers Squibb Company Recent Development
Table 65. Eli Lilly and Company Company Details
Table 66. Eli Lilly and Company Business Overview
Table 67. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 68. Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Eli Lilly and Company Recent Development
Table 70. F. Hoffmann-La Roche Ltd. Company Details
Table 71. F. Hoffmann-La Roche Ltd. Business Overview
Table 72. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 73. F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 74. F. Hoffmann-La Roche Ltd. Recent Development
Table 75. Five Prime Therapeutics, Inc. Company Details
Table 76. Five Prime Therapeutics, Inc. Business Overview
Table 77. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 78. Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Five Prime Therapeutics, Inc. Recent Development
Table 80. Genentech, Inc. Company Details
Table 81. Genentech, Inc. Business Overview
Table 82. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 83. Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 84. Genentech, Inc. Recent Development
Table 85. Incyte Corporation Company Details
Table 86. Incyte Corporation Business Overview
Table 87. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 88. Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 89. Incyte Corporation Recent Development
Table 90. Johnson & Johnson Company Details
Table 91. Johnson & Johnson Business Overview
Table 92. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 93. Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 94. Johnson & Johnson Recent Development
Table 95. MacroGenics, Inc. Company Details
Table 96. MacroGenics, Inc. Business Overview
Table 97. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 98. MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 99. MacroGenics, Inc. Recent Development
Table 100. Novartis AG Company Details
Table 101. Novartis AG Business Overview
Table 102. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 103. Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 104. Novartis AG Recent Development
Table 105. Oncogenex Pharmaceuticals, Inc. Company Details
Table 106. Oncogenex Pharmaceuticals, Inc. Business Overview
Table 107. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 108. Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 109. Oncogenex Pharmaceuticals, Inc. Recent Development
Table 110. PsiOxus Therapeutics Limited Company Details
Table 111. PsiOxus Therapeutics Limited Business Overview
Table 112. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product
Table 113. PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022) & (US$ Million)
Table 114. PsiOxus Therapeutics Limited Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Squamous Non-Small Cell Lung Cancer Therapeutics Product Picture
Figure 2. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size 2017-2028 (US$ Million)
Figure 4. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
Figure 5. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size 2017-2028 (US$ Million)
Figure 6. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share in Global 2017-2028
Figure 7. Squamous Non-Small Cell Lung Cancer Therapeutics Report Years Considered
Figure 8. Product Picture of BMS-906024
Figure 9. Product Picture of Buparlisib Hydrochloride
Figure 10. Product Picture of FP-1039
Figure 11. Product Picture of Ipilimumab
Figure 12. Product Picture of JNJ-42756493
Figure 13. Product Picture of Lenvatinib
Figure 14. Product Picture of Others
Figure 15. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type in 2022 & 2028
Figure 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017-2028) & (US$ Million)
Figure 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2017-2028)
Figure 18. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type in 2022 & 2028
Figure 19. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2017-2028) & (US$ Million)
Figure 20. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type (2017-2028)
Figure 21. Product Picture of Research Center
Figure 22. Product Picture of Hospital
Figure 23. Product Picture of Clinic
Figure 24. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application in 2022 & 2028
Figure 25. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017-2028) & (US$ Million)
Figure 26. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2017-2028)
Figure 27. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application in 2022 & 2028
Figure 28. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2017-2028) & (US$ Million)
Figure 29. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2017-2028)
Figure 30. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 31. U.S. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 32. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 33. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 34. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 35. France Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 36. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 37. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 38. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 39. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 40. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 41. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 42. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 43. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 44. Australia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 45. Taiwan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 46. Indonesia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 47. Thailand Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 48. Malaysia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 49. Philippines Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 50. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 51. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 52. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 53. Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 54. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
Figure 55. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 56. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 57. U.A.E Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
Figure 58. Ascenta Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 59. AstraZeneca Plc Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 60. AVEO Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 61. Bayer AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 62. BIND Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 63. Boehringer Ingelheim GmbH Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 64. Bristol-Myers Squibb Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 65. Eli Lilly and Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 66. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 67. Five Prime Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 68. Genentech, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 69. Incyte Corporation Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 70. Johnson & Johnson Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 71. MacroGenics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 72. Novartis AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 73. Oncogenex Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 74. PsiOxus Therapeutics Limited Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2017-2022)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Ascenta Therapeutics, Inc. AstraZeneca Plc AVEO Pharmaceuticals, Inc. Bayer AG BIND Therapeutics, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd. Five Prime Therapeutics, Inc. Genentech, Inc. Incyte Corporation Johnson & Johnson MacroGenics, Inc. Novartis AG Oncogenex Pharmaceuticals, Inc. PsiOxus Therapeutics Limited